LIGAND PHARMACEUTICALS INCORPORATED
Equity & Debt
| Fiscal Year | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| FY2018 | — | $560.9M | $117.2M |
| FY2019 | — | $767.2M | $71.5M |
| FY2020 | — | $709.5M | $47.6M |
| FY2021 | — | $821.2M | $19.5M |
| FY2022 | — | $597.5M | $45.0M |
Equity & Debt
| Fiscal Year | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| FY2018 | — | $560.9M | $117.2M |
| FY2019 | — | $767.2M | $71.5M |
| FY2020 | — | $709.5M | $47.6M |
| FY2021 | — | $821.2M | $19.5M |
| FY2022 | — | $597.5M | $45.0M |